BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9644320)

  • 1. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
    Nomura Y; Nakajima M; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study].
    Aoyama H; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 May; 25(6):853-65. PubMed ID: 9617324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer].
    Morimoto K; Abe O; Kinoshita H
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1565-73. PubMed ID: 9725050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
    Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocrine therapy for advanced or recurrent breast cancer].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
    Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
    Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
    Jiang Z; Song S; Liu X
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid receptor expression in endometria from women treated with tamoxifen.
    Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
    Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].
    Mitsuyama S; Nomura Y; Ohno S; Miyauchi M; Yamamoto N; Kimura T; Saku M; Miura S; Yoshikawa N; Tsujinaka T; Koh J; Ishida T; Abe O; Ohashi Y
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2071-7. PubMed ID: 16352931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.
    Falanga A; Toma S; Marchetti M; Palumbo R; Raffo P; Consonni R; Marziali S; Dastoli G; Barbui T
    Am J Hematol; 2002 May; 70(1):9-15. PubMed ID: 11994976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent development of endocrine treatment for breast cancer--new drugs and new treatment methods using tamoxifen].
    Sonoo H; Kurebayashi J
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2289-99. PubMed ID: 8259841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase I study of TAT-59 (a new antiestrogen) in breast cancer. TAT-59 Study Group].
    Nomura Y; Abe O; Enomoto K; Fujiwara K; Tominaga T; Hayashi K; Uchino J; Takahashi M; Hayasaka A; Asaishi K; Okazaki M; Abe R; Kimishima I; Kajiwara T; Haga S; Shimizu T; Miyazaki I; Noguchi M; Yoshida M; Miura S; Taguchi T; Oota J; Sakai K; Kinoshita H; Tashiro H
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):553-61. PubMed ID: 9530362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer].
    Asaishi K; Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):91-9. PubMed ID: 8422190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.